
Loading, please wait...

Loading, please wait...

Primary intracranial neoplasms present formidable management challenges, particularly when tumor biology displays intermediate aggressiveness. Clinicians managing WHO Grade 2 meningioma often encounter unpredictable biological behavior and substantial variability in recurrence risk. Over several decades, neurosurgeons and radiation oncologists have debated the optimal postoperative management strategy for these atypical tumors. While complete surgical extirpation represents the cornerstone of primary therapy, residual tumor cells frequently cause disease relapse. Therefore, refining postoperative risk assessment remains paramount for optimizing survival outcomes. A comprehensive landmark study now synthesizes three decades of published clinical experience using individual patient-level survival data, providing crucial clarity on surgical extent, radiation therapy, and tumor recurrence patterns.
Histopathological criteria for atypical meningiomas have undergone significant revisions over the past thirty years. Consequently, historical studies have produced heterogenous outcomes, complicating clinical decision-making. To resolve these ambiguities, investigators conducted a PRISMA-compliant systematic review pooling patient-level data from PubMed, MEDLINE, and Embase. Overall, the comprehensive synthesis evaluated 203 published studies comprising 640 unique patients. The primary objective focused on evaluating progression-free survival through rigorous Kaplan-Meier estimation and multivariable Cox proportional hazards modeling. Among 629 evaluable individuals, 337 patients experienced tumor recurrence or progression, representing an overall relapse rate of 53.6%. This high recurrence rate underscores the intermediate biological aggressiveness inherent to these intracranial lesions. Moreover, individual patient-level analysis allowed researchers to overcome the limitations of aggregated institutional series. By analyzing granular patient data across multiple eras, the study accounted for confounding baseline covariates and diverse therapeutic approaches. Clinicians can now interpret past institutional series against modern neurosurgical standards. Ultimately, this large-scale synthesis confirms that intermediate-grade meningiomas carry substantial lifetime recurrence risks that demand structured, risk-adapted postoperative monitoring.
Surgical excision remains the primary therapeutic intervention for intracranial meningiomas regardless of anatomical location. However, achieving complete macroscopic resection often proves difficult due to venous sinus invasion, skull base involvement, or adherence to critical neurovascular structures. The patient-level analysis identified surgical extent of resection as a pivotal branch point determining long-term progression risk. Patients undergoing subtotal resection faced a significantly higher risk of tumor recurrence compared to those achieving gross-total resection. Specifically, multivariable Cox regression demonstrated that incomplete resection increased the hazard of progression by eighty-seven percent. Thus, residual macroscopic disease provides an immediate nidus for cellular proliferation and aggressive local regrowth. In addition, these findings reinforce the classic surgical tenet prioritizing maximal safe resection whenever anatomically feasible. Nevertheless, aggressive pursuit of macroscopic clearance must not compromise neurological function. When residual tissue remains, clinicians must actively plan secondary interventions rather than adopting passive observation, because incomplete resection unmistakably accelerates disease relapse.
Postoperative radiation delivery remains a controversial topic in neuro-oncology, but subtotal resection provides a clear mandate for intervention. In this patient-level systematic review, adjuvant radiotherapy following incomplete surgical removal produced a dramatic therapeutic benefit. Specifically, adjuvant radiation reduced the relative hazard of disease progression by sixty-six percent compared to observation alone. Furthermore, this profound protective association remained exceptionally stable during landmark survival analysis, demonstrating enduring disease control rather than transient tumor delay. Residual atypical meningioma cells exhibit persistent mitotic activity and localized invasiveness. Consequently, immediate external-beam irradiation suppresses microscopic proliferation before substantial tumor mass accumulates. Delayed radiotherapy delivered only at symptomatic recurrence often achieves inferior local control compared to immediate adjuvant administration. Therefore, multidisciplinary neuro-oncology teams should routinely recommend adjuvant radiotherapy for patients with documented residual disease after surgery. Overall, the evidence firmly establishes immediate postoperative radiation as the standard of care for incompletely resected intermediate-grade lesions.
While the benefits of radiation therapy appear unambiguous after subtotal removal, management following gross-total resection presents an enduring clinical dilemma. Historically, clinicians debated whether complete surgical removal warrants immediate adjuvant radiotherapy or active radiographic surveillance. In the systematic review, adjuvant radiation delivered after gross-total resection demonstrated a less definitive survival advantage. Multivariable survival modeling revealed a non-significant hazard reduction of seventeen percent, with confidence intervals spanning unity. Consequently, routine upfront radiation for all completely excised atypical meningiomas remains controversial within the neurosurgical community. Recently, emerging prospective data, including the landmark phase three ROAM/EORTC-1308 trial, suggested meaningful recurrence reductions with adjuvant radiation after complete resection. However, clinicians must carefully weigh potential long-term neurocognitive deficits and radiation necrosis against recurrence prevention. Therefore, multidisciplinary teams must adopt personalized decision-making frameworks. Factors such as high mitotic index, brain invasion, complex skull base anatomy, and molecular biomarkers should guide treatment selection. In the absence of high-risk molecular features, structured magnetic resonance surveillance remains a reasonable strategy.
Technological advancements have expanded the therapeutic armamentarium available for cranial radiotherapy over the past several decades. Radiation oncologists frequently choose between fractionated external-beam radiotherapy and focused stereotactic radiosurgery for focal meningioma management. In an exploratory analysis within the systematic review, researchers compared progression-free survival between single-fraction stereotactic radiosurgery and conventional fractionated radiotherapy. Interestingly, the investigation identified no statistically significant difference in disease recurrence between these two radiation modalities. While single-fraction radiosurgery offers superior patient convenience and reduced treatment duration, fractionated regimens protect adjacent critical neurovascular structures and brain parenchyma. Therefore, radiation oncologists must tailor modality selection according to tumor volume, surgical bed geometry, and proximity to eloquent brain regions. Furthermore, the future of meningioma management increasingly relies on integrated genomic and epigenomic profiling. Molecular classification systems, including DNA methylation profiling, now identify aggressive biological subgroups far more accurately than histological grading alone. Consequently, clinicians should combine molecular diagnostics with resection extent to personalize adjuvant therapy, optimizing tumor control while preserving neurological function.
Extent of resection serves as a major prognostic determinant for disease recurrence. In the comprehensive systematic review, subtotal resection increased the progression hazard by eighty-seven percent compared to gross-total resection. Incomplete macroscopic clearance leaves residual proliferating cells, significantly accelerating local tumor regrowth and shortening long-term progression-free survival.
Yes, adjuvant radiotherapy provides substantial therapeutic benefit following subtotal resection. Patient-level survival analyses demonstrated that postoperative radiation reduced the risk of tumor progression by sixty-six percent compared to observation. Furthermore, this protective association remained durable across landmark analyses, firmly establishing immediate adjuvant radiotherapy as an essential standard for incompletely resected tumors.
The exploratory analysis revealed no statistically significant difference in progression-free survival between single-fraction stereotactic radiosurgery and fractionated radiotherapy. Both delivery techniques demonstrated comparable local control. Consequently, clinical selection depends primarily on lesion size, geographic location, proximity to sensitive cranial nerves, and multidisciplinary assessment of radiation toxicity risks for individual patients.
Disclaimer: This content is for informational and educational purposes only and should not be construed as clinical advice. Clinicians should exercise their independent judgment when managing individual patients. Refer to the latest local and national guidelines for clinical practice.
References
Qiu H et al. WHO Grade 2 meningioma across three decades: a systematic review with individual patient-level analysis of management and recurrence. J Neurooncol. 2026 Nov 16. doi: 10.1007/s11060-026-05880-1. PMID: 43037779.
Jenkinson MD et al. Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2026;408(10565):1420-1431.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A 30-year patient-level review examines recurrence and treatment outcomes in WHO Grade 2 meningioma. While adjuvant radiotherapy significantly benefits patients following subtotal resection, its role after gross-total resection demands personalized assessment based on emerging clinical evidence.
Today

A qualitative study evaluated the INCLUDE trial, a culturally tailored mobile diabetes prevention intervention. Findings highlight digital accessibility and community coaching as key facilitators, while time constraints and rigid dietary elements posed barriers, offering vital lessons for clinical practice.
Today

A large cohort study demonstrates that fetal growth restriction in a first pregnancy raises maternal cardiovascular risk within five years postpartum, including elevated rates of heart failure, stroke, and myocardial infarction. Clinicians must initiate proactive postpartum screening and cardiovascular prevention.
Today

An NHANES analysis reveals that meeting 24-hour movement guidelines significantly lowers the odds of cardiovascular disease, obesity, hypertension, and diabetes among adults with disabilities, emphasizing the power of combined physical activity, sleep, and limited sedentary time.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Today

A randomized trial in California evaluated a grocery support program for low-income, chronically ill adults. The intervention improved nutrition security by 2.8%, increased vegetable intake, boosted mental health scores, and reduced cost-related healthcare delays by 3.8%, showing the power of food-as-medicine.
Today